Cargando…

ROS1 amplification mediates resistance to gefitinib in glioblastoma cells

Glioblastoma (GBM) is the most aggressive brain tumor in adults and remains incurable despite multimodal intensive treatment regimens. The majority of GBM tumors show a mutated or overexpressed EGFR, however, tumors treated with tyrosine kinase inhibitors (TKIs) will inevitably recur highlighting th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aljohani, Hashim, Koncar, Robert F., Zarzour, Ahmad, Park, Byung Sun, Lee, So Ha, Bahassi, El Mustapha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653012/ https://www.ncbi.nlm.nih.gov/pubmed/25978031

Ejemplares similares

Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma
por: Furgason, John M., et al.
Publicado: (2015)

Comparative molecular profiling of HPV‐induced squamous cell carcinomas
por: Koncar, Robert F., et al.
Publicado: (2017)

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
por: Koncar, Robert F., et al.
Publicado: (2017)

Pemetrexed induces ROS generation and cellular senescence by attenuating TS‐mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC
por: Chen, Yun, et al.
Publicado: (2023)

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
por: Liu, Dongcheng, et al.
Publicado: (2022)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET
por: Oh, Ha-Na, et al.
Publicado: (2020)

Next-generation sequencing technologies: breaking the sound barrier of human genetics
por: Bahassi, El Mustapha, et al.
Publicado: (2014)

Krüppel‐like factor 4 promotes c‐Met amplification‐mediated gefitinib resistance in non‐small‐cell lung cancer
por: Feng, Wei, et al.
Publicado: (2018)

Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
por: Karim, Nagla Abdel, et al.
Publicado: (2014)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
por: Kim, Mi Seong, et al.
Publicado: (2020)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020)

Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance
por: Huang, Haohao, et al.
Publicado: (2021)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Trem2 mediated Syk-dependent ROS amplification is essential for osteoclastogenesis in periodontitis microenvironment
por: Weng, Yuteng, et al.
Publicado: (2020)

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib
por: Jin, Qian, et al.
Publicado: (2021)

Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification
por: Jang, Won-Jun, et al.
Publicado: (2014)

Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
por: Abdel-Karim, Nagla, et al.
Publicado: (2019)

GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy
por: Im, Ji Hye, et al.
Publicado: (2018)

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer
por: Song, Si Yeon, et al.
Publicado: (2022)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
por: Wu, Kai, et al.
Publicado: (2013)

The Regulation of ROS- and BECN1-Mediated Autophagy by Human Telomerase Reverse Transcriptase in Glioblastoma
por: Ding, Xuelu, et al.
Publicado: (2021)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

EGFR Amplification and Glioblastoma Stem-Like Cells
por: Liffers, Katrin, et al.
Publicado: (2015)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
por: Wang, Xiaomeng, et al.
Publicado: (2021)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_btj69j0007dqhgd5bba0a44ae7